What is Inhibitor Therap's earnings per share (EPS)?

Inhibitor Therap (INTI) reported diluted earnings per share of $-0.02 for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Inhibitor Therap Financials

INTI

Source SEC Filings (10-K/10-Q) Updated Mar 25, 2026 Currency USD FYE March

This page shows Inhibitor Therap (INTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.98x

For every $1 of reported earnings, Inhibitor Therap generates $0.98 in operating cash flow (-$3.2M OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$3.3M

YoY+1.2%

Inhibitor Therap reported -$3.3M in net income in fiscal year 2025. This represents an increase of 1.2% from the prior year.

EPS (Diluted)

$-0.02

YoY+0.0%

Inhibitor Therap earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

173M

YoY+0.1%

5Y CAGR-14.3%

10Y CAGR-3.5%

Inhibitor Therap had 173M shares outstanding in fiscal year 2025. This represents an increase of 0.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$1.7M

YoY+0.8%

5Y CAGR+55.7%

10Y CAGR+0.1%

Inhibitor Therap invested $1.7M in research and development in fiscal year 2025. This represents an increase of 0.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

INTI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.7M+0.8%	$1.7M+21.8%	$1.4M+22356.4%	$6K+25.4%	$5K-97.4%	$185K
SG&A Expenses	$1.7M-12.4%	$2.0M-2.4%	$2.0M+210.5%	$652K+103.4%	$320K-63.3%	$874K
Operating Income	-$3.4M+6.3%	-$3.7M-7.4%	-$3.4M-417.5%	-$658K-102.2%	-$325K+69.3%	-$1.1M
Interest Expense	N/A	N/A	N/A	$23K+56.6%	$15K+1302.4%	$1K
Income Tax	N/A	N/A	N/A	$55K	$0	$0
Net Income	-$3.3M+1.2%	-$3.3M-10.3%	-$3.0M-125.0%	$12.1M+4153.9%	-$299K+71.8%	-$1.1M
EPS (Diluted)	$-0.020.0%	$-0.020.0%	$-0.02-166.7%	$0.03	$0.00	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$378K+16.0%	$326K+37.9%	$236K	N/A	$370K+54.2%	$240K-7.9%	$260K	N/A
SG&A Expenses	$363K-1.8%	$370K-15.6%	$438K	N/A	$444K+28.4%	$345K-32.9%	$514K	N/A
Operating Income	-$741K-6.5%	-$696K-3.1%	-$675K	N/A	-$813K-39.0%	-$585K+24.5%	-$775K	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$712K-7.9%	-$660K-4.3%	-$633K	N/A	-$731K-45.7%	-$502K+26.7%	-$685K	N/A
EPS (Diluted)	$0.00	$0.00	$0.00	N/A	$0.00	$0.00	$0.00	N/A

INTI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$5.7M-36.4%	$8.9M-25.3%	$12.0M+20271.4%	$59K-55.4%	$132K
Current Assets	N/A	$5.7M-36.4%	$8.9M-25.3%	$12.0M+20271.4%	$59K-45.2%	$107K
Cash & Equivalents	N/A	$5.6M-36.6%	$8.8M-26.0%	$12.0M+38923.1%	$31K-59.2%	$75K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$3.7M+1.2%	$3.7M-0.4%	$3.7M0.0%	$3.7M+5.4%	$3.5M
Current Liabilities	N/A	$710K+6.7%	$665K-2.0%	$679K-0.1%	$680K+59.8%	$425K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$2.0M-62.4%	$5.3M-36.3%	$8.3M+329.1%	-$3.6M-7.8%	-$3.4M
Retained Earnings	N/A	-$52.1M-6.8%	-$48.8M-6.6%	-$45.8M+20.7%	-$57.7M-0.9%	-$57.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$3.1M-19.8%	$3.9M-13.3%	$4.5M-20.9%	$5.7M-11.7%	$6.5M-10.1%	$7.2M-8.0%	$7.8M-12.9%	$8.9M
Current Assets	$3.1M-20.0%	$3.8M-13.4%	$4.4M-22.4%	$5.7M-11.7%	$6.5M-10.1%	$7.2M-8.0%	$7.8M-12.9%	$8.9M
Cash & Equivalents	$3.0M-20.4%	$3.7M-13.5%	$4.3M-22.9%	$5.6M-12.1%	$6.4M-10.1%	$7.1M-7.6%	$7.7M-13.1%	$8.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.1M-1.9%	$3.2M+1.2%	$3.2M-15.0%	$3.7M+21.8%	$3.0M+0.3%	$3.0M-3.8%	$3.2M-13.9%	$3.7M
Current Liabilities	$88K-37.5%	$140K+47.8%	$95K-86.7%	$710K+1492.5%	$45K+25.4%	$36K-77.2%	$156K-76.6%	$665K
Long-Term Debt	$44K-15.1%	$52K-10.8%	$58K	N/A	N/A	N/A	N/A	N/A
Total Equity	$3K-99.5%	$716K-47.1%	$1.4M-31.9%	$2.0M-41.7%	$3.4M-17.7%	$4.1M-10.8%	$4.6M-12.2%	$5.3M
Retained Earnings	-$54.1M-1.3%	-$53.4M-1.3%	-$52.8M-1.2%	-$52.1M-2.8%	-$50.7M-1.5%	-$50.0M-1.0%	-$49.5M-1.4%	-$48.8M

INTI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$3.2M+0.1%	-$3.2M-19.7%	-$2.7M-123.0%	$11.7M+5426.2%	-$220K+73.3%	-$825K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	-$411K-328.3%	$180K+2.3%	$176K+82.2%	$97K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$761K-30.4%	-$584K+54.6%	-$1.3M-66.6%	-$771K-7.1%	-$720K-23.6%	-$583K+49.7%	-$1.2M-66.0%	-$698K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

INTI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-168.2%-110.9pp	-57.3%-203.2pp	145.9%	N/A	N/A
Return on Assets	N/A	-58.6%-24.8pp	-33.8%-134.9pp	101.1%+609.1pp	-508.0%+294.9pp	-802.9%
Current Ratio	N/A	8.03-5.4	13.45-4.2	17.64+17.6	0.09-0.2	0.25
Debt-to-Equity	N/A	1.87+1.2	0.69+0.3	0.44+1.5	-1.02+0.0	-1.04
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-20625.1%-20532.9pp	-92.2%-45.4pp	-46.8%	N/A	-21.5%-9.3pp	-12.1%+2.6pp	-14.8%	N/A
Return on Assets	-22.7%-5.8pp	-16.9%-2.8pp	-14.1%	N/A	-11.3%-4.3pp	-7.0%+1.8pp	-8.8%	N/A
Current Ratio	35.00+7.6	27.36-19.3	46.68+38.7	8.03-136.8	144.78-57.1	201.91+151.9	50.01+36.6	13.45
Debt-to-Equity	12.79+12.7	0.07+0.0	0.04-1.8	1.87+1.0	0.89+0.2	0.73+0.1	0.68-0.0	0.69
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Pharmala Biotech MDXXF

$8.1M

Bioxytran Inc BIXT

$4.9M

Betterlife Pharma Inc BETRF

$7.1M

Genflow Biosciences GENFF

$16.3M

Frequently Asked Questions

Is Inhibitor Therap profitable?

No, Inhibitor Therap (INTI) reported a net income of -$3.3M in fiscal year 2025.

What is Inhibitor Therap's operating cash flow?

Inhibitor Therap (INTI) generated -$3.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How much does Inhibitor Therap spend on research and development?

Inhibitor Therap (INTI) invested $1.7M in research and development during fiscal year 2025.

How many shares does Inhibitor Therap have outstanding?

Inhibitor Therap (INTI) had 173M shares outstanding as of fiscal year 2025.

Are Inhibitor Therap's earnings high quality?

Inhibitor Therap (INTI) has an earnings quality ratio of 0.98x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.